X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Sensi Products unveils new pharma-grade and child-resistant packaging

Content Team by Content Team
2nd May 2019
in Packaging & Logistic, Press Statements
Sensi packaging

Sensi Products, the licensed cannabis manufacturer of Sensi Chew, has introduced new pharma-grade and child-resistant packaging.

The new California compliant packaging, which features an informational insert to improve the user experience, has been designed for cannabis infused chocolate caramels.

The new packaging and automated manufacturing process will help the company to meet the growing market demand for its cannabis edibles.

Available in more than 240 licensed dispensaries and delivery services across California, Sensi Chews are provided in 90mg pack with 10-9mg individual doses.

The company is providing a family of nine products under three specific categories.

Classic is comprised of Sativa, Indica, Hybrid, while Specialty includes added formulations for insomnia, energy, and sexual enhancement. CBD is comprised of CBD-only, 1:1 CBD to THC, and CBD for Insomnia.

Sensi Products CSMO Lisa Tollner said: “Since its inception Sensi Chew has focused on helping users select a product based on time of day use and will continue to use our ‘Daytime. Nighttime. Anytime’ product segmentation to assist consumers in knowing when to use which chew. All products are color-coded to help users as well as budtenders to easily identify each product.”

Sensi Chew Insomnia is a major cannabis sleep-aid product on the market, said the company.

The company has made an investment in research on sleep, pain, and anxiety, and is planning to launch focused reports on the findings.

Sensi Products CEO Edic Sliva said: “Our goal is to bring Sensi Chew Insomnia to the millions of people who struggle to sleep each night.

“Sensi Chew Insomnia can replace the harmful side-effects of traditional sleep aids to give users a healthy alternative and the deep restful sleep they deserve.”

Sensi Products was established by Edic Sliva and Lisa Tollner in 2013. Edic Sliva is also the founder of Microlux that offers electronics, design, and manufacturing services for medical devices, consumer goods, automotive and military products.

Lisa Tollner established Cintara Corp, which is a full-service brand marketing firm that provides services to firms in high tech, healthcare, consumer goods, and hospitality industries.

 

Previous Post

SGS Implements Veeva Vault Clinical Trial Management System across Global Network

Next Post

Manufacturing growth sees surging demand at CPhI South East Asia

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Next Post
CPhI South East Asia

Manufacturing growth sees surging demand at CPhI South East Asia

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In